Stevanato Group S.p.A.


SKU: STVN-1 Category:


Stevanato Group S.p.A.: Leveraging Market Trends in Biologics and Self-Administration!


Stevanato Group’s first quarter 202rb performance underlined some critical challenges while also highlighting its robust positioning within the pharmaceutical supply sector. In a period marred by the ripples of the pandemic induced stockpiling, Stevanato Group’s revenue saw a slight decrement of 1% year-over-year, totaling EUR 236 million. This decline predominantly stemmed from the accelerated industry-wide destocking processes, particularly impacting their EZ-fill vials segment.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!